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Despite ongoing research efforts, drug addiction continues to pose a largely unmet medical need and is 
fueled by high rates of recidivism. The need for more effective interventions aimed at relapse 
prevention has led many researchers to re-evaluate current strategies and explore new and revisit old 
approaches to the problem. In their paper in the current issue of “Neuropsychopharmacology”, 
Heinsbroek, Furbish and Peters use a rat model to explore the potential utility of an aversive 
“counterconditioning” approach, in which aversive stimuli are paired with drug associated 
cues/context with the goal of dampening their ability to elicit drug-seeking behavior. Using aversive 
conditioning to modify behavior is among the earliest ideas of psychology, dating back to the early 
20th century when John B. Watson and Rosalie Rayner demonstrated that such an approach could be 
used to establish fear reactions to a previously rewarding stimulus (a lab rat) in a 9-month-old child. 
In their paper, Heinsbroek and colleagues test the ability of the kappa opioid receptor (KOR) agonist, 
U50,488 (U50), a compound with established aversive properties, to counter-condition cocaine-
associated cues, thereby attenuating their ability to evoke cocaine-seeking behavior. In the study, rats 
underwent repeated cocaine self-administration, followed by a 7-day abstinence period, after which 
they received a single dose of the KOR agonist or vehicle prior to re-introduction into the drug 
environment under extinction conditions in which responding no longer resulted in cocaine delivery. In 
addition to reducing responding during the initial retrieval session, the single U50 treatment 
significantly attenuated later reinstatement of cocaine seeking upon response-contingent cue 
presentation. This effect was dependent on KOR-induced activation of p38 MAP kinase signaling. The 
authors interpret their findings as reflecting KOR-mediated counterconditioning such that the new 
association between the aversive effects of the KOR agonist and the unrewarded operant response 
within the drug context counteracts the previously established cocaine association. They conclude 
that, to the extent that drug-associated stimuli can be isolated and introduced into a laboratory 
setting, KOR agonist delivery may be used to establish new aversive associations that reduce the 
likelihood of future drug-seeking behavior and relapse. Overall, the authors’ findings are consistent 
with previous work demonstrating that KOR agonists can counteract the rewarding effects of cocaine 
itself (see e.g., refs. [1] and [2]). 
The concept of using aversive conditioning to curb drug use is not a new one. Indeed, studies dating 
back to the 1970’s have attempted to establish associations between aversive and drug-related stimuli 
during therapy with the objective of reducing recidivism with limited success (see e.g., ref. [3]). 
However, several interesting observations by Heinsbroek and colleagues may better define how 
aversive stimuli or, more specifically, signaling processes engaged by aversive stimuli, may be better 
leveraged to reduce relapse risk. 
The first observation is that the ability of KOR agonist administration prior to the retrieval session to 
“counter-condition” cue-induced cocaine seeking was not reproduced by lithium chloride (LiCl) 
administration at a dose that produces place aversion, reward devaluation, and gastric malaise. This 
finding was somewhat surprising, considering that KORs have been reported to mediate the aversive 
effects of stressors (see e.g., ref. [4]), although KOR mediation of LiCl effects has not been 
demonstrated. However, the finding is consistent with a previous report that the ability of footshock to 
“counter-condition” drug-cue associations resulting from cocaine self-administration is transient at 
best (see e.g., [5]). It may be that parallel processes engaged by LiCl and other stressors can offset or 
interfere with the effects of KOR activation that attenuate later drug seeking. Thus, the authors’ 
findings suggest that specifically targeting the KOR and its downstream signaling mechanisms (e.g., 
p38/MAPK) can provide a pharmacological means for isolating components of the aversive response 
that can counteract or disrupt drug associations and attenuate later relapse susceptibility. 
The second observation may provide insight regarding the precise KOR-regulated component of the 
aversive response that underlies the observed effect on cocaine seeking. The authors found that the 
ability of U50 to reduce later drug seeking was dependent not only on administration of U50 but also 
access to the previously active lever in the context suggesting a new or modified association is 
occurring that influences subsequent behavior. KORs are broadly distributed in areas of the brain that 
regulate associative learning, including the NAc and VTA. In fact, VTA KOR activation is required for 
both kappa agonist-induced reductions in NAc dopamine concentration and aversion learning [6]. The 
ability of KOR-induced signaling to inhibit dopamine neurons in the VTA [7] or alter downstream 
dopamine signaling via effects on NAc MSNs [8] could be particularly relevant to the authors’ 
observations. It has long been proposed that a key function of dopamine is to encode error in reward 
prediction [9]. Elevated dopaminergic signaling in response to drug-predictive cues incentivize behavior 
while pauses in dopamine release are associated with reward omission and may reduce the likelihood 
of subsequent responding. In the latter case, an intriguing potential explanation for the observed 
response-dependent effects of U50 is that KOR activation produces a pharmacological enhancement of 
negative prediction error via suppressed dopaminergic signaling. Notably, suppression of dopamine 
signaling by KOR activation could also account for the acute attenuation of drug seeking by U50 during 
the initial retrieval session, as signaling in the nucleus accumbens has been implicated in the 
incentivizing properties of predictive cues. While appealing, this possible explanation has its 
limitations. First, LiCl, which does not produce the same effects on later cue-induced cocaine seeking, 
has also been demonstrated to attenuate dopamine signaling [10]. However, the mechanism, duration, 
and intensity of LiCl action is vastly different than U50 and all of these factors are relevant for proper 
associative learning. Second, although p38 has been implicated in many KOR effects, it may not be 
required for the ability of KOR agonists to attenuate dopamine release, at least not stimulated 
dopamine release as measured using in vivo cyclic voltammetry in mice with a constitutive loss of p38 
in midbrain dopamine neurons [7]. It is likely that both KOR-mediated reductions in dopamine signaling 
and KOR-mediated p38 activation are required for proper aversion learning. This raises the intriguing 
possibility that these distinguishable KOR-mediated signals may each contribute to different aspects of 
an animal’s ability to learn about an aversive outcome. If this is the case, then discerning their 
respective contributions to this process could lead to the development of better therapeutics with 
fewer off-target dysphoric effects. Despite these limitations, the possibility that KOR regulation of 
dopaminergic signaling via actions in the VTA and/or nucleus accumbens contributes to the observed 
effects merits further investigation. Although the authors did not conduct brain region-specific 
manipulations in their paper, their findings establish an important starting point for a more targeted 
investigation of the precise mechanisms through which KOR agonists diminish the ability of drug-
associated cues to elicit drug seeking. 
Although the findings in the paper are important, there are a number of practical considerations that 
may limit immediate clinical application. First, ideal interventions involving counterconditioning 
approaches will require the identification and isolation of relevant drug-associated cues and their 
recapitulation in a therapy environment in a way that incorporates the operational act of drug seeking. 
While challenging, it is possible that such obstacles could be overcome through the use of guided 
imagery, possibly facilitated by modern technology such as virtual reality platforms. A bigger problem 
may be the limited efficacy of the approach. Extinction-based approaches that successfully mitigate 
drug-seeking behaviors often are limited to the extinction-context, thus latent or suppressed drug 
seeking behavior remains susceptible to renewal/relapse. Therefore, a demonstration that the kappa-
mediated enhancement of operant extinction, when acquired outside of the drug context, carries over 
to reduced drug seeking within the original drug context would increase enthusiasm for kappa 
mediated counterconditioning approaches. Furthermore, although U50 administration significantly 
attenuated cue-induced drug seeking, blockade of reinstatement was incomplete. In human 
populations, where such levels of drug-seeking behavior will likely translate to use and, as a result, 
drug-cue associations will be re-established. Finally, the undesirable effects of KOR agonist drugs in 
human populations, which includes intense dysphoria and psychotomimetic effects has been well-
documented and could limit clinical utility. However, as newer medications targeting KORs (e.g., biased 
agonists) and downstream signaling mechanisms are developed, the feasibility of using them 
therapeutically should increase. 
In conclusion, while more work is needed to understand the underlying mechanism, the paper by 
Heinsbroek and colleagues raises the intriguing possibility that, to the extent that aversion-based 
approaches used in conjunction with extinction-based therapy represent a viable option for treating 
drug addiction, KOR agonist medications may provide an opportunity for more precise targeting of 
aversion-related processes that reduce the likelihood that drug-associated cues will serve as relapse 
triggers. 
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